 |
||||||||||||
 |
||||||||||||
|
Since the days
of Hippocrates, medication non-adherence has been a significant health
care problem. Recent research suggests that the total economic cost of
non-adherence is $290 billion per year in the United States, rivaling
the burden of cardiovascular disease. New quality measures have been
established and implemented by CMS offering health plans unprecedented
financial bonuses from improving medication adherence at a population
level. Moreover, the cost effectiveness of efforts to improve adherence
have never been greater given recent reductions in the average cost of
many common chronic disease drug therapies due to the expiration of
patent protection for many blockbuster drugs. From another perspective, preventable hospital readmissions are a threat to patient safety, a burden to numerous stakeholders, occur far too often, and contribute to rising health care costs. Nationally, preventable readmissions cost an estimated $25 billion per year. Hospitals, attending physicians and other providers have been focusing on reducing preventable readmissions, as they seek to improve quality and improve outcomes, and due to Medicare policy and payment changes in this regard. Health plans, employers, care management organizations and other stakeholders also have a significant vested interest in managing readmissions for all applicable patient populations. Despite recent momentum addressing medication adherence, major progress on improving adherence nationally is lacking because of the difficulty of identifying the specific patients who could most benefit from care management support to address common causes of non-adherence. Readmissions management also is challenged by the ability to predict those most as risk for readmission. This session connects the dots between the issues of Medication Adherence, Readmissions Management and Predictive Analytics; providing insight into the correlation between medication adherence and readmissions; the application of predictive models for medication adherence; and the implications for improving outcomes, efficiencies and performance in a variety of care settings and scenarios by through identification of those at risk for low medication adherence. Join us on Wednesday, March 13th, 2013, as Blue Cross & Blue Shield Rhode Island's Doctor Brian Wolf discusses their analytics initiative that correlated medication adherence with readmissions, and their continuing efforts to leverage resulting improvements in their readmissions management. Doctor Wolf's presentation will be followed by Aaron McKethan, PhD of RxAnte's examination of how an analytic platform that starts with a robust calibration process, claims and clinical data, and accurate predictions, results in the more efficient achievement of better outcomes than targeting strategies based on lagging adherence indicators. |
||||||||||||
 |
||||||||||||
Participants will be able to:
|
||||||||||||
 |
||||||||||||
|
Interested attendees would include:
Attendees would represent organizations including:
|
||||||||||||
 |
||||||||||||
 |
||||||||||||
|
||||||||||||
 |
|
Return to HealthExecWire Archive Menu
|
